ProMIS Neurosciences (PMN) News Today $0.50 0.00 (-0.91%) Closing price 05/30/2025 03:59 PM EasternExtended Trading$0.52 +0.02 (+4.00%) As of 05/30/2025 05:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PMN Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period ProMIS Neurosciences Inc. Announces Completion of First Cohort in PRECISE-AD Trial for PMN310 in Alzheimer's DiseaseMay 13, 2025 | nasdaq.comProMIS Neurosciences Stock Price, Quotes and Forecasts | NASDAQ:PMN | BenzingaMay 13, 2025 | benzinga.comProMIS Neurosciences Announces First Quarter 2025 Financial ResultsMay 12, 2025 | globenewswire.comProMIS Neurosciences reports FY24 EPS 11c vs. ($1.07) last yearMarch 31, 2025 | markets.businessinsider.comProMIS Neurosciences Inc.: ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent HighlightsMarch 31, 2025 | finanznachrichten.deProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent HighlightsMarch 31, 2025 | globenewswire.comProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer's Disease/Parkinson's Disease 2025 International ConferenceMarch 24, 2025 | globenewswire.comProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual MeetingMarch 13, 2025 | globenewswire.comProMIS Neurosciences to Participate in the 37th Annual Roth ConferenceMarch 11, 2025 | globenewswire.comProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer’s DiseaseFebruary 25, 2025 | markets.businessinsider.comProMIS Neurosciences doses first patiets in Phase 1b PRECISE-AD trialFebruary 25, 2025 | markets.businessinsider.comProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer's DiseaseFebruary 25, 2025 | globenewswire.comProMIS Neurosciences Separates With Gavin T. Malenfant as Chief Operating OfficerFebruary 20, 2025 | marketwatch.comProMIS Neurosciences seperates from COO Malenfant, terminates COO positionFebruary 20, 2025 | markets.businessinsider.comProMIS Neurosciences, Inc. (NASDAQ:PMN) Insider Neil Cashman Acquires 15,000 SharesFebruary 13, 2025 | insidertrades.comProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech ConferenceJanuary 29, 2025 | financialpost.comProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech ConferenceJanuary 29, 2025 | financialpost.comProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech ConferenceJanuary 29, 2025 | globenewswire.comProMIS Neurosciences anticipates PRECISE-AD interim patient data in 1H26January 13, 2025 | markets.businessinsider.comProMIS Neurosciences Issues Letter to ShareholdersJanuary 13, 2025 | globenewswire.comProMIS Neurosciences Initiates Phase 1b Clinical Trial (PRECISE-AD) in Alzheimer’s DiseaseJanuary 10, 2025 | markets.businessinsider.comProMIS Neurosciences Inc.: ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent HighlightsNovember 15, 2024 | finanznachrichten.deProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent HighlightsNovember 14, 2024 | globenewswire.comProMIS Neurosciences presents data from PMN310 Phase1a trialOctober 31, 2024 | markets.businessinsider.comProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer's Disease ConferenceOctober 30, 2024 | globenewswire.comProMIS Neurosciences, Inc. (NASDAQ:PMN): Among The 10 Oversold Canadian Stocks to Buy Right NowOctober 24, 2024 | finance.yahoo.comProMIS Neurosciences (NASDAQ:PMN) Stock, Insider Trading ActivityOctober 5, 2024 | benzinga.comProMIS Neurosciences (NASDAQ:PMN) Stock, Short Interest ReportOctober 5, 2024 | benzinga.comProMIS Neurosciences, Inc. (NASDAQ:PMN) Director Madge K. Shafmaster Buys 60,000 SharesSeptember 25, 2024 | insidertrades.comProMIS Neurosciences Inc PMNSeptember 19, 2024 | morningstar.comProMIS Neurosciences to Showcase PMN310's Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral NeurosciencesSeptember 12, 2024 | globenewswire.comProMIS Neurosciences to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 5, 2024 | globenewswire.comProMIS Neurosciences, Inc. (NASDAQ:PMN) Director Buys $12,500.00 in StockAugust 17, 2024 | insidertrades.comProMIS Neurosciences Announces Second Quarter 2024 Financial Results and Recent HighlightsAugust 8, 2024 | markets.businessinsider.comProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024August 1, 2024 | globenewswire.comProMIS Neurosciences regains NASDAQ complianceJuly 31, 2024 | uk.investing.comProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer's Association International ConferenceJuly 30, 2024 | globenewswire.comWestwood and Majesticks aiming to dig deeper as LIV Golf heads to JCB ClubJuly 26, 2024 | msn.comProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's TrialJuly 26, 2024 | globenewswire.comProMIS Neurosciences Announces Up to $122.7 Million Private Placement FinancingJuly 26, 2024 | globenewswire.comPMN Stock Earnings: ProMIS Neurosciences Beats EPS for Q1 2024May 15, 2024 | msn.comProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent HighlightsMay 14, 2024 | globenewswire.comTrading was temporarily halted for "PMN" at 09:05 AM with a stated reason of "LULD pause." Trading set to resume at 09:05 AM. May 1, 2024 | marketbeat.comProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed AntibodiesApril 30, 2024 | globenewswire.comProMIS Neurosciences (PMN) Price Target Increased by 9.38% to 8.93April 17, 2024 | msn.comProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALSApril 9, 2024 | globenewswire.comProMIS Neurosciences to Present in Upcoming Investor Conferences in AprilApril 4, 2024 | globenewswire.comProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent HighlightsApril 1, 2024 | globenewswire.comProMIS Neurosciences Strengthens Global Intellectual Property PortfolioMarch 11, 2024 | globenewswire.comProMIS Neurosciences to Present at the 2024 BIO CEO & Investor ConferenceFebruary 22, 2024 | globenewswire.com Get ProMIS Neurosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for PMN and its competitors with MarketBeat's FREE daily newsletter. Email Address PMN Media Mentions By Week PMN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PMN News Sentiment▼1.440.87▲Average Medical News Sentiment PMN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PMN Articles This Week▼20▲PMN Articles Average Week Get ProMIS Neurosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for PMN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CervoMed News ZIVO Bioscience News Zura Bio News Adlai Nortye News Skye Bioscience News Surrozen News PDS Biotechnology News Assertio News Clearside Biomedical News Citius Oncology News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PMN) was last updated on 5/31/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProMIS Neurosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ProMIS Neurosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PMN Stock Free PMN Stock Alerts